RE:RE:RE:Volume ticking up... I highly doubt it.
Expanded trials coming.
New CEO coming.
Balance sheet void of cash.
Company living off of options conversions and small raises for a few years.
Financials all caught up.
Reading between the lines. Something big is coming to fund all of this.
It's clear, no one expected the founder to pass. But when he did. The only thing that made sense. Was to put this on the shelf until the son was old and wise enough to take over. That takes place July 1. There is a reason they halted for him being appointed. I think it will soon lead to being a very big deal.
The company would have never had to endure a through period that painful, without the passing of the founder.
While very sad. It's a buying opportunity.
Previously what held this stock back. Was the chemo drugs it could latch on to. Didn't need them. They had patents and no need to better their cash machines.
But those patents are now expiring and the genererics are all over it. One chemo drug in our market lost over $500m to this factor in just the first year of generic competition. With their losses expected to deepen further.
By combining apc's conjugate therapy with existing chemotherapy drugs. They are creating a bio best option that will allow them to fight back against generic competition.
Some VC friends I respect a bunch. Think this stock should be $1.00+. Gotta feeling by sometime this summer. We may get there! Then again I could be wrong. It could happen sooner! Haha